HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept
{
"count": 82,
"next": "http://api.gregory-ms.com/trials/source/12/?format=api&page=5",
"previous": "http://api.gregory-ms.com/trials/source/12/?format=api&page=3",
"results": [
{
"title": "Osmotin Plant Protein for Progressive Multiple Sclerosis",
"summary": "<b>Condition</b>: Progressive Multiple Sclerosis<br /><b>Intervention</b>: Dietary Supplement: Osmotin<br /><b>Sponsors</b>: Ospedale Policlinico San Martino; Italian Multiple Sclerosis Foundation; S. Andrea Hospital<br /><b>Recruiting</b>",
"link": "http://classic.clinicaltrials.gov/ct2/show/NCT05937802?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
"published_date": "2023-07-10T16:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2023-07-10T12:20:42.339666Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
},
{
"title": "Reproductive Options in Inherited Skin Diseases",
"summary": "<b>Conditions</b>: Ichthyosis; Palmoplantar Keratoses; Epidermolysis Bullosa; Ectodermal Dysplasia; Basal Cell Nevus Syndrome; Birt-Hogg-Dube Syndrome; Tuberous Sclerosis; Xeroderma Pigmentosum; Cutis Laxa; Albinism\n<br /><b>Sponsors</b>: Maastricht University Medical Center\n<br /><b>Enrolling by invitation</b>",
"link": "https://clinicaltrials.gov/study/NCT06330324?cond=Multiple+Sclerosis",
"published_date": "2024-03-26T04:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2024-04-09T13:25:51.343946Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
},
{
"title": "A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.",
"summary": "<b>Conditions</b>: Relapsing Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Progressive Relapsing Multiple Sclerosis\n<br /><b>Interventions</b>: Drug: Tolebrutinib; Drug: Placebo; Drug: Teriflunomide\n<br /><b>Sponsors</b>: Sanofi\n<br /><b>Recruiting</b>",
"link": "https://clinicaltrials.gov/study/NCT06372145?cond=Multiple+Sclerosis",
"published_date": "2024-04-17T04:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2024-04-27T09:47:04.932377Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": [
{
"category_id": 11,
"category_description": "Based on the following article, this item was added to the Observatory page.\r\n\r\n> Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial\r\n\r\nSource [The Lancet](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00237-4/fulltext)",
"category_name": "Tolebrutinib",
"category_slug": "tolebrutinib",
"category_terms": [
"tolebrutinib",
"SAR442168"
],
"article_count": 3
}
]
},
{
"title": "National Registry of Rare Kidney Diseases",
"summary": "<b>Conditions</b>: Adenine Phosphoribosyltransferase Deficiency; AH Amyloidosis; AHL Amyloidosis; AL Amyloidosis; Alport Syndrome; Atypical Hemolytic Uremic Syndrome; Autoimmune Distal Renal Tubular Acidosis; Autosomal Recessive Proximal Renal Tubular Acidosis; Autosomal Recessive Distal Renal Tubular Acidosis; Autosomal Dominant Polycystic Kidney Disease; Autosomal Recessive Polycystic Kidney Disease; Bartter Syndrome; BK Nephropathy; C3 Glomerulopathy With Monoclonal Gammopathy; C3 Glomerulopathy; Calciphylaxis; Crystalglobulinaemia; Crystal-storing Histiocytosis; Cystinosis; Cystinuria; Dense Deposit Disease; Dent Disease; Denys-Drash Syndrome; Dominant Hypophosphataemia With Nephrolithiasis and/or Osteoporosis; Drug Induced Fanconi Syndrome; Drug-Induced Hypomagnesemia; Drug-Induced Nephrogenic Diabetes Insipidus; Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy; Fabry Disease; Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis; Familial Primary Hypomagnesemia With Hypocalcuria; Familial Primary Hypomagnesaemia With Normocalciuria; Familial Renal Glucosuria; Fanconi Renotubular Syndrome 1; Fanconi Renotubular Syndrome 2; Fanconi Renotubular Syndrome 3; Fibrillary Glomerulonephritis; Fibromuscular Dysplasia; Focal Segmental Glomerulosclerosis; Generalised Pseudohypoaldosteronism Type 1; Gitelman Syndrome; Heavy-Metal-Induced Fanconi Syndrome; Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes; Hereditary Renal Hypouricemia; Hereditary Hypophosphatemic Rickets With Hypercalciuria; Hyperuricaemic Nephropathy; IgA Nephropathy; Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits; Inherited Renal Cancer Syndromes; Intracapillary Monoclonal IgM Without Cryoglobulin; Intraglomerular/Capillary Lymphoma/Leukaemia; Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type; Liddle Syndrome; Light Chain Cast Nephropathy; Light Chain Proximal Tubulopathy Without Crystals; Light Chain Proximal Tubulopathy With Crystals; Lowe Syndrome; Membranous Nephropathy; Membranoproliferative Glomerulonephritis; Medullary Cystic Kidney Disease; Minimal Change Nephropathy; Mitochondrial Disease Of The Kidney; Monoclonal Immunoglobulin Deposition Disease; Nail Patella Syndrome; Nephrogenic Diabetes Insipidus; Nephrogenic Syndrome of Inappropriate Antidiuresis; Nephronophthisis; Primary Hypomagnesemia With Secondary Hypocalcemia; Primary Hyperoxaluria; Proliferative Glomerulonephritis With Monoclonal IgG Deposits; Proximal Tubulopathy Without Crystals; Pseudohypoaldosteronism Type 1, 2A-2E; Pure Red Cell Aplasia; Retroperitoneal Fibrosis; Sickle Cell Nephropathy; Shiga Toxin Associated Haemolytic Uraemic Syndrome; Steroid Resistant Nephrotic Syndrome; Steroid-Sensitive Nephrotic Syndrome; Thin Basement Membrane Nephropathy; Thrombotic Microangiopathy With Monoclonal Gammopathy; Type 1 Cryoglobulinaemic Glomerulonephritis; Tuberous Sclerosis; Unclassified Monoclonal Gammopathy Of Renal Significance; Vasculitis\n<br /><b>Sponsors</b>: UK Kidney Association\n<br /><b>Recruiting</b>",
"link": "https://clinicaltrials.gov/study/NCT06065852?cond=Multiple+Sclerosis",
"published_date": "2023-10-04T04:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2023-10-04T16:22:33.999871Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
},
{
"title": "Kappa Index Versus Csf Oligoclonal Bands in Diagnosis of ms and Prediction of Disease Activity",
"summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Interventions</b>: Diagnostic Test: kappa index\n<br /><b>Sponsors</b>: Assiut University\n<br /><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/study/NCT06372977?cond=Multiple+Sclerosis",
"published_date": "2024-04-18T04:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2024-04-27T09:47:05.087801Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
},
{
"title": "REtinal Markers In Neuroinflammatory Diseases (\"REMIND\")",
"summary": "<b>Conditions</b>: Multiple Sclerosis; Neuroinflammatory Diseases\n<br /><b>Interventions</b>: Diagnostic Test: Optical coherence tomography (OCT); Diagnostic Test: Static retinal vessel analyzer; Diagnostic Test: Dynamic retinal vessel analyzer; Diagnostic Test: Laser speckle flowgraphy system; Other: Questionnaire\n<br /><b>Sponsors</b>: University Hospital, Basel, Switzerland; University of Basel\n<br /><b>Recruiting</b>",
"link": "https://clinicaltrials.gov/study/NCT06369766?cond=Multiple+Sclerosis",
"published_date": "2024-04-17T04:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2024-04-27T09:47:04.961490Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
},
{
"title": "Resistance Training and Corticospinal Excitability in Multiple Sclerosis",
"summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Interventions</b>: Behavioral: Progressive resistance training\n<br /><b>Sponsors</b>: University of Aarhus; Aarhus University Hospital; University of Copenhagen\n<br /><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/study/NCT06374108?cond=Multiple+Sclerosis",
"published_date": "2024-04-18T04:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2024-04-27T09:47:04.883585Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
},
{
"title": "AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy",
"summary": "<b>Conditions</b>: Mesial Temporal Lobe Epilepsy\n<br /><b>Interventions</b>: Genetic: AAV9-hSyn1-miGRIK2\n<br /><b>Sponsors</b>: uniQure France SAS\n<br /><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/study/NCT06063850?cond=Multiple+Sclerosis",
"published_date": "2023-10-03T04:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2023-10-04T00:42:29.415068Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
},
{
"title": "Blood Flow Restriction Training in Multiple Sclerosis",
"summary": "<b>Conditions</b>: MS\n<br /><b>Interventions</b>: Other: strengthening ex with BFR training; Other: strengthening ex\n<br /><b>Sponsors</b>: Cairo University\n<br /><b>Recruiting</b>",
"link": "https://clinicaltrials.gov/study/NCT06143930?cond=Multiple+Sclerosis",
"published_date": "2023-11-22T05:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2023-11-22T13:43:10.591844Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
},
{
"title": "ALS Phase II Study of NX210c",
"summary": "<b>Conditions</b>: Amyotrophic Lateral Sclerosis\n<br /><b>Interventions</b>: Drug: NX210c; Drug: Placebo\n<br /><b>Sponsors</b>: Axoltis Pharma; ACT4ALS network\n<br /><b>Not yet recruiting</b>",
"link": "https://clinicaltrials.gov/study/NCT06365216?cond=Multiple+Sclerosis",
"published_date": "2024-04-15T04:00:00Z",
"source": "Clinical Trials.gov",
"publisher": null,
"container_title": null,
"relevant": null,
"ml_prediction_gnb": null,
"ml_prediction_lr": null,
"ml_prediction_lsvc": null,
"discovery_date": "2024-04-26T04:25:56.792827Z",
"noun_phrases": null,
"doi": null,
"access": null,
"takeaways": null,
"categories": []
}
]
}